Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (öffnet neues Fenster)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Quelle‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Indiziert‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (öffnet neues Fenster)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (öffnet neues Fenster)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Quelle‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Indiziert‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (öffnet neues Fenster)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (öffnet neues Fenster)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Quelle‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Indiziert‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (öffnet neues Fenster)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (öffnet neues Fenster)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Quelle‎: Blood 2003;102(4):1529-30.

Indiziert‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (öffnet neues Fenster)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (öffnet neues Fenster)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Quelle‎: Transfusion 2007;47(10):1830-6.

Indiziert‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (öffnet neues Fenster)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (öffnet neues Fenster)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Quelle‎: Iran J Blood Cancer 2009;1(4):147-50.

Indiziert‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (öffnet neues Fenster)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (öffnet neues Fenster)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Quelle‎: Int J Hematol 2012;95(1):51-6.

Indiziert‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (öffnet neues Fenster)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (öffnet neues Fenster)

Perrine SP.

Quelle‎: Pediatr Ann 2008;37(5):339-46.

Indiziert‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (öffnet neues Fenster)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (öffnet neues Fenster)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Quelle‎: Sci Rep. 2022;12(1):2752.

Indiziert‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (öffnet neues Fenster)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (öffnet neues Fenster)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Quelle‎: Haematologica 2004;89(10):1172-8.

Indiziert‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (öffnet neues Fenster)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (öffnet neues Fenster)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Quelle‎: Arch Iran Med 2009;12(3):295-7.

Indiziert‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (öffnet neues Fenster)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (öffnet neues Fenster)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Quelle‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Indiziert‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (öffnet neues Fenster)

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (öffnet neues Fenster)

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Quelle‎: Pediatr Hematol Oncol 1997;14(3):285-7.

Indiziert‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215 (öffnet neues Fenster)

Fetal globin gene inducers: novel agents and new potential. (öffnet neues Fenster)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Quelle‎: Ann N Y Acad Sci 2010;1202:158-64.

Indiziert‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (öffnet neues Fenster)